Free Trial
NASDAQ:CASI

CASI Pharmaceuticals (CASI) Stock Price, News & Analysis

CASI Pharmaceuticals logo
$2.23 -0.06 (-2.62%)
Closing price 08/27/2025 04:00 PM Eastern
Extended Trading
$2.21 -0.02 (-1.08%)
As of 08/27/2025 05:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About CASI Pharmaceuticals Stock (NASDAQ:CASI)

Key Stats

Today's Range
$2.19
$2.36
50-Day Range
$1.18
$2.47
52-Week Range
$1.09
$7.67
Volume
40,474 shs
Average Volume
3.73 million shs
Market Capitalization
$27.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00
Consensus Rating
Buy

Company Overview

CASI Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
81st Percentile Overall Score

CASI MarketRank™: 

CASI Pharmaceuticals scored higher than 81% of companies evaluated by MarketBeat, and ranked 201st out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    CASI Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    CASI Pharmaceuticals has received no research coverage in the past 90 days.

  • Read more about CASI Pharmaceuticals' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of CASI Pharmaceuticals is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of CASI Pharmaceuticals is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    CASI Pharmaceuticals has a P/B Ratio of 18.58. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about CASI Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    0.93% of the float of CASI Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    CASI Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in CASI Pharmaceuticals has recently increased by 3.64%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    CASI Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    CASI Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.93% of the float of CASI Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    CASI Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in CASI Pharmaceuticals has recently increased by 3.64%, indicating that investor sentiment is decreasing.
  • News Sentiment

    CASI Pharmaceuticals has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for CASI Pharmaceuticals this week, compared to 0 articles on an average week.
  • Search Interest

    2 people have searched for CASI on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, CASI Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    21.24% of the stock of CASI Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 22.23% of the stock of CASI Pharmaceuticals is held by institutions.

  • Read more about CASI Pharmaceuticals' insider trading history.
Receive CASI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CASI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CASI Stock News Headlines

“Sell Nvidia before earnings”
Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has been chasing the AI giant, Eric says its biggest customers are now its biggest competitors — and that could spell trouble ahead. Instead, he’s urging investors to consider a little-known hardware company that’s already starting to take off. In fact, while Nvidia has slipped over the past 30 days, this “off-the-radar” stock is up 18% — and Eric believes the run is just beginning.tc pixel
CASI Pharmaceuticals Inc Valuation - Morningstar
See More Headlines

CASI Stock Analysis - Frequently Asked Questions

CASI Pharmaceuticals' stock was trading at $2.83 at the start of the year. Since then, CASI shares have decreased by 21.2% and is now trading at $2.23.

CASI Pharmaceuticals Inc. (NASDAQ:CASI) announced its earnings results on Friday, May, 16th. The biotechnology company reported ($0.69) EPS for the quarter, missing analysts' consensus estimates of ($0.61) by $0.08. The biotechnology company had revenue of $6.24 million for the quarter, compared to analysts' expectations of $7.39 million. CASI Pharmaceuticals had a negative net margin of 129.05% and a negative trailing twelve-month return on equity of 972.55%.

CASI Pharmaceuticals shares reverse split on Wednesday, June 1st 2022.The 1-10 reverse split was announced on Wednesday, June 1st 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

CASI Pharmaceuticals' top institutional shareholders include Foresite Capital Management VI LLC (6.40%).
View institutional ownership trends
.

Shares of CASI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that CASI Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Arista Networks (ANET), Broadcom (AVGO), Novo Nordisk A/S (NVO), Adobe (ADBE) and ServiceNow (NOW).

Company Calendar

Last Earnings
5/16/2025
Today
8/27/2025
Next Earnings (Estimated)
8/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CASI
CIK
895051
Employees
180
Year Founded
1991

Price Target and Rating

High Price Target
$4.00
Low Price Target
$4.00
Potential Upside/Downside
+79.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.55)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$39.26 million
Net Margins
-129.05%
Pretax Margin
-125.26%
Return on Equity
-972.55%
Return on Assets
-77.33%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.81
Quick Ratio
0.68

Sales & Book Value

Annual Sales
$28.54 million
Price / Sales
0.96
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.12 per share
Price / Book
18.58

Miscellaneous

Outstanding Shares
12,300,000
Free Float
9,687,000
Market Cap
$27.43 million
Optionable
Optionable
Beta
0.63

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:CASI) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners